There is a growing need for life sciences companies to train their teams on specialty drugs and prepare them to have effective conversations with stakeholders in the specialty marketplace. Beyond their specialty product knowledge, these customer-facing teams need to be conversant about the specialty marketplace and the providers’ practice and decision-making process.
Specialty drugs are changing the biopharmaceutical and healthcare industries. They are redefining what diseases are treatable, how profitability is determined, and how costs are managed. The pressure on specialty drug prices will rise as more biosimilars arrive in 2023. Industry analysts predict specialty drugs will account for nearly 60% of drug spending in developed markets and half of the global drug spending by 2025. They expect new specialty drugs focused on rare diseases will help spur that growth.
CMR Institute recently updated our specialty market training content, which includes seven eModules and an eBrief, to reflect the specialty drug market changes and learning requirements of life sciences sales professionals.
